Emergence of Functional δ-Opioid Receptors Induced by Long-Term Treatment with Morphine

Junyi Ma, Yong Zhang, Alex E. Kalyuzhny, and Zhizhong Z. Pan

Department of Anesthesiology and Pain Medicine, the University of Texas-MD Anderson Cancer Center, Houston, Texas (J.M., Y.Z., Z.Z.P.); and Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota (A.E.K.)

ABSTRACT

Opioid analgesics remain the choice for the treatment of moderate to severe pain. Recent research has established that the μ-opioid receptor is predominantly responsible for mediating many opioid actions, including analgesia and opioid tolerance. However, the function of δ-opioid receptors is rather puzzling at present, with inconsistent reports of system effects by agonists of δ-opioid receptors. The functional interaction between μ-opioid receptors and δ-opioid receptors is also poorly understood. In this study, we demonstrated that in a brainstem site critically involved in opioid analgesia, agonists of δ-opioid receptors, ineffective in opioid naive rats, significantly inhibit presynaptic GABA release in the brainstem neurons from morphine-tolerant rats. In membrane preparation from control brainstem tissues, Western blot detected no proteins of δ-opioid receptors, but consistent δ-opioid receptor proteins were expressed in membrane preparation from morphine-tolerant rats. Immunohistochemical studies revealed that long-term morphine treatment significantly increases the number of δ-opioid receptor-immunoreactive varicosities that appose the postsynaptic membrane of these neurons. The colocalization of δ-opioid receptor-immunoreactive varicosities with the labeling of the GABA-synthesizing enzyme glutamic acid decarboxylase is also significantly increased. From a behavioral perspective, activation of δ-opioid receptors in the brainstem nucleus, lacking an effect in opioid naive rats, became analgesic in morphine-tolerant rats and significantly reduced morphine tolerance. These findings indicate that long-term morphine treatment induces the emergence of functional δ-opioid receptors and δ-opioid receptor-mediated analgesia, probably through receptor translocation to surface membrane in GABAergic terminals. They also suggest that opioid drugs with preference for δ-opioid receptors may have better therapeutic effect in a μ-opioid-tolerant state.

Opioids are still the most effective analgesics for the treatment of moderate to severe pain, such as cancer pain. Recent studies, particularly those using opioid receptor knockout mice, have clearly established that the μ-opioid receptor is predominantly responsible for mediating major opioid actions, including analgesia, reward, and the development of opioid tolerance and dependence (Matthes et al., 1996; Sora et al., 1997; Kieffer, 2000). However, the function of the δ-opioid receptor remains puzzling at present (Fields, 2004). Abundant immunoreactivity for δ-opioid receptors has been illustrated in brain areas important for opioid analgesia (Arvidsson et al., 1995; Cheng et al., 1995; Commons et al., 2001), but no cellular effect of δ-opioid receptors on neurons in these brain areas has been demonstrated in normal conditions. From a behavioral standpoint, agonists of δ-opioid receptors produce little to weak analgesic effects under normal conditions in animal studies and in clinical applications (Inturrisi, 2002; Fields, 2004). Some of the δ-opioid receptor agonist-induced analgesia has been argued to result from the effect of recruited μ-opioid receptors (Kieffer, 2000; Scherrer et al., 2004). Other δ-opioid receptor agonist-mediated analgesia may be attributed to normally functional δ-opioid receptors in the spinal cord. The reasons for the lack of significant brain functions of δ-opioid receptors in pain modulation have thus far been unknown. The functional interaction between δ-opioid receptors and μ-opioid receptors under conditions of long-term opioid treatment is also poorly understood.

A significant clinical problem in pain management with current opioid therapies is the development of analgesic tolerance to and dependence on repeatedly used agonists of μ-opioid receptors such as morphine. Because agonists of μ-opioid receptors seem to remain the primary and widely

ABBREVIATIONS: NRM, nucleus raphe magnus; IPSC, inhibitory postsynaptic current; PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GAD, glutamic acid decarboxylase; CTAP, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH$_2$; norBNI, nor-binaltorphimine dihydrochloride; DAMGO, [D-Ala^2,N-Me-Phe^4,Gly^5-ol]-enkephalin; RT-PCR, reverse transcription-PCR.

used analgesics for pain in the foreseeable future, the understanding of functions of δ-opioid receptors under conditions of short- and long-term treatment with opioids is of great significance for improvement of current opioid therapies by increasing analgesic efficacy and reducing tolerance. The nucleus raphe magnus (NRM) in the medulla is a crucial brainstem site for opioid-induced analgesia. Neurons in the NRM directly modulate pain transmission at the spinal cord via their descending projections to the dorsal horn (Scholz and Woolf, 2002; Fields, 2004). We have previously characterized the cellular mechanisms for μ-opioid receptor-mediated analgesia in the NRM and its functional interactions with the κ-opioid receptor (Pan et al., 1990, 1997). In this study, we examined functions of δ-opioid receptors in morphine-naive rats and in rats undergoing long-term morphine treatment, morphine-tolerant rats in both NRM slice preparations in vitro, and a rat model of morphine tolerance in vivo. We focused on a class of NRM neurons that lacks postsynaptic μ-opioid receptors, is activated by agonists of analgesic μ-opioid receptors through disinhibition (inhibition of GABA synaptic inputs), and presumably inhibits spinal pain transmission through descending inhibition (Pan et al., 1997; Fields, 2004).

Materials and Methods

All procedures involving the use of animals conformed to the guidelines set by the University of Texas-MD Anderson Cancer Center Animal Care and Use Committee.

Long-Term Morphine Treatment. Male Wistar rats underwent long-term treatment with morphine to induce morphine tolerance as described previously (Pan, 2003). For whole-cell recordings, neonatal rats (9–14 days old) were randomly divided into two groups. One group was injected (i.p.) with increasing doses of morphine twice daily for 6 days. The morphine dose was 10 mg/kg on day 1 and was increased by 5 mg/kg each day to reach the maximum doses of 30 mg/kg on days 5 and 6. The other group was injected with saline for controls. The injection volume was 0.1 to 0.3 ml. Neonatal rats were used for better visualization of neurons in brain slices for visualized whole-cell recording. It has been shown that the physiological and pharmacological properties of neurons from these young rats are indistinguishable from those of adult rats (Pan et al., 1997). For molecular, immunohistochemical, and behavioral experiments, rats (200–300 g) were treated with morphine by subcutaneous implantation of morphine pellets. One morphine pellet (75 mg) was implanted on day 1, and two more morphine pellets were implanted on day 4. The same numbers of placebo pellets were implanted on the same schedule in a separate group of rats as controls. On day 7, brain slice preparations were made for whole-cell recordings, or behavioral experiments were conducted, or NRM tissues were taken for analysis. Although developmental differences exist, our previous studies have shown that those cellular studies in slices from neonatal rats serve well as guidelines for mechanisms underlying behavioral effects observed in adult rats (Pan et al., 1997; Bie et al., 2005).

Brain Slice Preparations. The rat brain was cut in a vibratome in cold (4°C) physiological saline to obtain brainstem slices (200 μm thick) containing the NRM. A single slice was submerged in a shallow recording chamber and perfused with preheated (35°C) physiological saline (126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH_2PO_4, 1.2 mM $MgCl_2$, 2.4 mM $CaCl_2$, 11 mM glucose, and 25 mM $NaHCO_3$, saturated with 95% O_2 and 5% CO_2, pH 7.2–7.4). Slices from morphine-treated rats (tolerant group), as well as slices from saline-treated rats (control group), were maintained in 1 μM morphine in vitro throughout the recording experiment to prevent morphine withdrawal as described previously (Ingram et al., 1998; Bie and Pan, 2005). A third group of slices (normal group) from saline-treated rats

and kept in morphine-free solution was used as controls for the short-term morphine treatment.

Whole-Cell Recordings and Data Analysis. Visualized whole-cell voltage-clamp recordings were obtained from identified NRM neurons with a glass pipette (resistance, 3–5 MΩ) filled with a solution containing 126 mM KCl, 10 mM NaCl, 1 mM $MgCl_2$, 11 mM EGTA, 10 mM HEPES, 2 mM ATP, and 0.25 mM GTP, pH adjusted to 7.3 with KOH; osmolarity, 280 to 290 mOsM. An AxoPatch-1D amplifier and AxoGraph software (Axon Instruments, Inc., Union City, CA) were used for data acquisition and on-line/off-line data analyses. A seal resistance of 2 GΩ or above and an access resistance of 15 MΩ or less were considered acceptable. Series resistance was optimally compensated. The access resistance was monitored throughout the experiment. All NRM cells included in this study were identified as a cell type that lacks the μ-opioid receptor, according to the criteria described in our previous study (Pan et al., 1990). Electrical stimuli of constant current (0.25 ms, 0.2–0.4 mA) were used to evoke a GABA-mediated inhibitory postsynaptic current (IPSC), with bipolar stimulating electrodes placed close to the recorded cell. With KCl-filled electrodes, GABA IPSCs were in an inward direction (Pan et al., 1990). Miniature IPSCs were obtained in 60-s epochs in the presence of tetrodotoxin (1 μM). The AxoGraph software was used to detect and measure the amplitude and intervals of synaptic events and to analyze their distribution data. On average, cells displayed 128 ± 29 synaptic events of GABA IPSCs during a 60-s period in normal conditions (n = 11). All GABA IPSCs were recorded in the presence of glutamate receptor antagonists D-(−)-2-amino-5-phosphonopentanoic acid (30 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM) with a holding potential of −60 mV. Drugs were generally applied through the bath solution unless specified otherwise.

Relative Quantitative Real-Time PCR and Western Blotting. Both methods have been published previously (Bie et al., 2005). NRM tissues were taken from morphine- or placebo-treated rats (n = 9 in each group). The primer sequences for PCR were: δ-opioid receptor: TGGGTCTTGGCTTCAGGTGT (forward), CGTGCATAC-CACTGCTCCAT (reverse); and GAPDH: TGCACCACCAACTGCT-TAGC (forward), GGCATGGACTGTGGTCATGAG (reverse).

Real-time PCRs were performed using SYBR Green RT-PCR Reagents kit and the ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). The GAPDH gene was used as an internal normalizer. Data were analyzed using the $2^{-\Delta\Delta Ct}$ method described by Livak and Schmittgen (2001). For Western blotting, NRM tissues from morphine- (n = 10) and placebo- (n = 8) treated rats were homogenized and divided into two parts to extract total and membrane proteins separately. Total proteins were prepared after tissue lysis and centrifugation for SDS-polyacrylamide gel electrophoresis. Membrane protein was extracted with a Membrane Protein Extraction Reagent kit (Pierce, Rockford, IL). Samples were incubated overnight with a primary antibody for δ-opioid receptors (1:2000; Chemicon, Temecula, CA) and for GAPDH (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). Immunoreactive proteins were detected by enhanced chemiluminescence (ECL Advance kit; GE Healthcare, Little Chalfont, Buckinghamshire, UK). The intensity of bands was quantitatively analyzed with the software Kodak 1D v.3 (Eastman Kodak Co., Rochester, NY). For Endo F treatment, total protein samples were incubated with 1 μl of Endo F1, F2, or F3 and respective 5× reaction buffer (Native Protein Deglycosylation Kit NDEGLY; Sigma, St. Louis, MO) at 37°C for 2 to 5 h. The reaction products were analyzed on SDS-polyacrylamide gel electrophoresis.

Quantitative Immunohistochemistry. The general methods are similar to those reported previously (Kalyuzhny et al., 1996; Kalyuzhny and Wessendorf, 1998). Serial sections (10 μm) containing the NRM were cut from the brainstem of fixed rats pretreated with morphine (n = 4) or placebo (n = 4). Sections were processed for double-labeling immunofluorescence using rabbit antisera directed against the cloned δ-opioid receptor (1:1000 dilution; a gift from Dr. Bob Elde, College of Biological Sciences, University of Minnesota,

St. Paul, MN) (Arvidsson et al., 1995) and mouse monoclonal antibodies against glutamic acid decarboxylase (GAD)-6 (1:200 dilution) (Kalyuzhny and Wessendorf, 1998). For apposition experiments, sections were incubated with δ-opioid receptor antiserum and then counterstained with Fluoro Nissl Green (Quinn et al., 1995). Quantitative analysis of confocal microscopic images was conducted on a 408×136-μm area within the NRM on four randomly selected sections per rat in each group. The number of single-labeled δ-opioid receptors and GAD varicosities and the number of double-labeled δ-opioid receptors/GAD varicosities were quantified with custom-designed image analysis software (MVS Pacific, Minneapolis, MN). Profiles were defined as double-labeled for δ-opioid receptors and GAD if both appeared in profiles overlapping (yellow color) after merging of pseudocolored images of δ-opioid receptors (red color) and GAD (green color). NRM neurons were considered apposed by δ-opioid receptor-immunoreactive profiles if there was no conceivable distance observed between δ-opioid receptor-immunoreactive varicosities and cell membrane counterstained with Fluoro Nissl Green in confocal images.

Microinjection and Behavioral Experiments. For NRM microinjection, a rat was anesthetized with sodium pentobarbital (50 mg/kg i.p.) and restrained in a stereotaxic apparatus. A 26-gauge double-guide cannula (Plastics One, Roanoke, VA) was inserted into the brain and aimed at the NRM (anteroposterior, -10.0 from the bregma; lateral, 0; dorsoventral, -10.5 from the dura) (Paxinos and Watson, 1986). The guide cannula was then cemented in place to the skull and securely capped. The rat was allowed to recover for 5 days from the surgery before implantation of morphine or placebo pellets for tolerance induction and control. Morphine tolerance was assessed by constructing cumulating dose-response curves for short-term morphine treatment in both control and morphine-treated groups. The morphine doses used were 0.1, 0.3, 0.6, 1, and 3 mg/kg for control rats and 1, 3, 6, 10, and 30 mg/kg for rats undergoing long-term morphine treatment. The time between morphine doses was 45 min. Pain threshold was measured by the tail-flick test on a freely moving rat with a Hargreaves analgesic instrument (Stoelting Co., Wood Dale, IL). Tail-flick latency to a heat stimulus was measured every 5 min. The heat intensity was set to elicit stable baseline latencies with a cut-off time of 10 s. The antinociceptive effect of short-term treatment with morphine was measured 30 min after morphine injection and expressed as maximum possible effect (MPE) [MPE = (test latency − baseline)/(cutoff − baseline)]. The EC_{50} values were obtained by fitting the morphine dose-response curve with the logistic equation and Kaleidagraph software (Abelbeck/Synergy, Reading, PA). After development of morphine tolerance, a single NRM microinjection of deltorphin (0.5 μg) or deltorphin plus naltriben (20 ng) was made 15 min before the first morphine dose through a 33-gauge double-injector with an infusion pump at a rate of 0.2 μl/min. The total volume for microinjection was 1 μl. The injection sites for the NRM were histologically verified afterward by injecting 0.5 μl of a blue dye through the injector. The confined effect within the NRM of this microinjection method has been demonstrated in our previous study (Bie et al., 2005).

Statistical Analyses and Materials. General numerical data were statistically analyzed with Students' t tests and presented as S.E.M. Statistic analysis of miniature IPSCs was performed using the Statview software with the Kolmogorov-Smirnov test. Behavioral results were statistically analyzed by an analysis of variance for repeated measures and the Tukey-Kramer test post hoc analysis. Morphine and placebo pellets were kindly supplied by the National Institute on Drug Abuse (Bethesda, MD). All other drugs were purchased from Sigma or Tocris Cookson (Ellisville, MO).

Results

We first examined the effect of δ-opioid receptor agonists in NRM neurons that lacked μ-opioid receptors using whole-cell voltage-clamp recording in NRM slices in vitro. Focal electri-

cal stimulation evoked an IPSC in the presence of glutamate receptor antagonists D-(−)-2-amino-5-phosphonopentanoic acid (30 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM), and glycine receptor antagonist strychnine (10 μM). The IPSC was completely abolished by the $GABA_A$ receptor antagonist bicuculline (30 μM; control, 217.6 $\pm$ 48.1 pA; bicuculline, 12.9 $\pm$ 2.1 pA; $n = 6$, $p < 0.01$; Fig. 1A). In normal slices from saline-treated rats under normal, morphine-free conditions (normal group), bath application of selective δ-opioid receptor agonist deltorphin (1 μM) failed to change the holding current in any cell tested ($n = 8$), indicating a general lack of functional postsynaptic δ-opioid receptors in this type of NRM neuron. Deltorphin (1 μM) also failed to alter the IPSC amplitude in these neurons of the normal slice group (control, 239.0 $\pm$ 46.9 pA; deltorphin, 240.5 $\pm$ 40.0 pA; $n = 18$, $p > 0.05$; Fig. 1C). In control slices from saline-treated rats maintained in 1 μM morphine in vitro (control group), deltorphin (1 μM) did not change the amplitude of evoked GABA IPSCs in every cell tested (con-

Fig. 1. Long-term morphine treatment induces δ-opioid receptor-mediated inhibition of evoked GABA IPSCs in neurons of the NRM. A, representative evoked IPSCs recorded with KCl-filled pipettes in controls and in the presence of $GABA_A$ receptor antagonist bicuculline (30 μM, left) or in the presence of the selective agonist of δ-opioid receptor deltorphin (1 μM, right) in NRM slices from saline-treated rats. B, GABA IPSCs in control and in deltorphin without (left) or with (right) the addition of selective antagonist of δ-opioid receptors naltriben (10 μM) in NRM neurons from rats undergoing long-term treatment with morphine. C, summarized data of deltorphin effects in NRM slices from saline-treated rats and maintained in vitro in morphine-free solution (normal group) or in 1 μM morphine (control group), and in NRM slices in 1 μM morphine from morphine-tolerant rats with or without naltriben. Numbers in columns indicate cell numbers. Scales in A apply to both A and B. Error bars are standard error of means. ∗∗, $p < 0.01$.

trol, 224.2 ± 30.2 pA; deltorphin, 209.1 ± 27.9 pA; n = 16, p > 0.05; Fig. 1, A and C). This indicates a general absence of functional δ-opioid receptors on GABAergic terminals innervating these neurons in control conditions.

However, in slices (from rats undergoing long-term treatment with morphine) maintained in 1 μM morphine in vitro to prevent morphine withdrawal (tolerant group), deltorphin at the same concentration (1 μM) significantly reduced the amplitude of GABA IPSCs in nine of 20 (45%) neurons surveyed (control, 298.1 ± 52.9 pA; deltorphin, 178.5 ± 25.1 pA, n = 9, p < 0.01; Fig. 1, B and C). The maximum inhibition was 36.1 ± 8.2% of controls. The addition of the selective δ-opioid receptor antagonist naltriben (10 μM) blocked this deltorphin effect (control, 217.4 ± 31.3 pA, deltorphin, 163.7 ± 24.5 pA, deltorphin plus naltriben, 210.5 ± 25.9 pA, n = 6, p > 0.05 compared with control; Fig. 1, B and C). The μ-opioid receptor-selective antagonist CTAP (1 μM) did not alter the deltorphin-induced inhibition (CTAP, 288.3 ± 29.9 pA; CTAP plus deltorphin, 209.0 ± 21.8 pA; n = 5, p < 0.05) and neither did the selective κ-opioid receptor antagonist nor-binaltorphimine dihydrochloride (norBNI, 1 μM) (norBNI, 235.1 ± 58.6 pA; norBNI plus deltorphin, 170.8 ± 44.5 pA; n = 4, p < 0.05). These results suggest that the emerged deltorphin inhibition of GABA IPSCs is selectively mediated by δ-opioid receptors.

To determine the synaptic site of this action of δ-opioid receptors, we examined the deltorphin effect on GABAergic miniature IPSCs in the presence of tetrodotoxin (1 μM). In slices of control group, deltorphin (1 μM) had no effect on either the frequency or amplitude of GABA miniature IPSCs (Fig. 2, A, B, and F). However, in identified neurons whose evoked IPSCs were inhibited by deltorphin in slices of the tolerant group, deltorphin (1 μM) also significantly decreased the miniature IPSC frequency (control, 1.47 ± 0.36 Hz; deltorphin, 0.85 ± 0.17 Hz; n = 5, p < 0.05; Fig. 2, C, D, and F) without altering the IPSC amplitude (Fig. 2, E and F). No deltorphin effect was observed on either frequency or amplitude of GABA miniature IPSCs in the normal slice group (frequency: control, 2.14 ± 0.49 Hz; deltorphin, 2.30 ± 0.55 Hz; amplitude: control, 41.0 ± 3.1 pA; deltorphin, 40.9 ± 3.0 pA; n = 11, p > 0.05). These observations indicate that the emerged inhibition of GABA IPSCs by δ-opioid receptors is caused by reduction of presynaptic GABA release from GABAergic terminals.

This emergence of functional δ-opioid receptors could be due to an increased expression of δ-opioid receptors in the nucleus through transcriptional up-regulation and/or up-regulated protein translation. To determine whether that was the case, we used real-time RT-PCR to determine changes in the expression level of mRNA for δ-opioid receptors in the NRM. The amplification plots of signals for δ-opioid receptors showed that the averaged cycle threshold (C_t) in NRM tissues taken from placebo-treated rats and from morphine-treated rats was 33.91 and 33.51, respectively (ΔC_t = 0.4, Fig. 3A).

Fig. 2. Long-term morphine treatment induces deltorphin inhibition of presynaptic GABA release. A and B, plots of cumulative distribution of frequency (A) and amplitude (B) of GABA miniature IPSCs in an NRM neuron from a saline-treated rat. C–E, representative current traces of miniature IPSCs (C) and distribution plots of miniature IPSC frequency (D) and amplitude (E) in control and in the presence of deltorphin in an NRM neuron from a morphine-treated rat. F, summarized data of deltorphin effects on miniature IPSCs in neurons from the two groups of rats. ∗, p < 0.05.


Fig. 3. Long-term morphine treatment increases membrane proteins of δ-opioid receptors in the NRM. A and B, amplification plot of real-time RT-PCR for δ-opioid receptor mRNA (A) and normalized -fold change in δ-opioid receptor mRNA (B) in placebo-treated rats and morphine-tolerant rats. C, representative lanes of Western blots of membrane proteins of δ-opioid receptors (top), total proteins of δ-opioid receptors (middle), and total GAPDH proteins (bottom) in the NRM from placebo-treated rats and morphine-tolerant rats. The molecular mass was 72 kD for δ-opioid receptors and 37 kD for GAPDH. D, normalized percent change of total proteins of δ-opioid receptors in the NRM from the two groups of rats. E, total proteins of δ-opioid receptors in the NRM from placebo and tolerant rats after incubation with endoglycosidases F1, F2, and F3. The molecular mass after the Endo F treatment was 72 kD. Plac, placebo.

After normalization to internal reference GAPDH, relative quantitative analysis showed that there was a 0.74-fold increase in δ-opioid receptor mRNA in the NRM from morphine-treated rats, but that increase did not reach statistical significance ($p = 0.18$; Fig. 3B). We then used Western blot to determine changes in both total proteins of δ-opioid receptors and membrane proteins of δ-opioid receptors in the NRM after long-term morphine treatment. We found no detectable δ-opioid receptor protein in membrane preparations from placebo-treated rats ($n = 8$), but in NRM tissues from morphine-treated rats ($n = 10$), membrane proteins of δ-opioid receptors were consistently present in the NRM from all 10 rats (Fig. 3C). In contrast, no significant difference was detected in total proteins of δ-opioid receptors, normalized to GAPDH, between NRM tissues from placebo- and morphine-treated rats (Fig. 3, C and D). To examine the contribution of protein glycosylation to the molecular mass of the δ-opioid receptor, total protein samples were incubated in endoglycosidases F1, F2, and F3 to remove potential N-linked oligosaccharides on the receptor protein. As shown in Fig. 3E, the molecular mass of the protein was still close to 72 kDa, indicating that glycosylation does not significantly contribute to the molecular mass of δ-opioid receptors in this NRM. Thus, it seems that long-term morphine treatment induces only a moderate up-regulation, if any, of δ-opioid receptor mRNA but largely increases δ-opioid receptor proteins in surface membrane, with no significant change in total proteins of δ-opioid receptors as determined by the Western blot technique in a morphine-dependent state.

G-protein-coupled receptors, including opioid receptors, are dynamically regulated through the mechanism of receptor trafficking and membrane insertion (Tan et al., 2004). We next used immunohistochemistry and quantitative confocal microscopy to examine expression and trafficking of δ-opioid receptors. We found that the total number of varicosities immunoreactive for δ-opioid receptors in the NRM from morphine-treated rats significantly increased by 73.4% ($p < 0.01$), whereas there was no significant change in total labeling for the GAD (average in 16 images from four rats in each treatment group; Fig. 4). Colocalization of δ-opioid receptor-

and GAD-immunoreactive varicosities also was significantly increased from 0 to 1.75 ± 0.30 per examined NRM area of the same images (Fig. 4, B and C). To examine potential synaptic contacts of presynaptic δ-opioid receptors on postsynaptic cell membrane, we determined changes in δ-opioid receptor-immunoreactive varicosities apposing the membrane of NRM neurons. Quantitative analysis revealed a significant increase in the number of δ-opioid receptor-immunoreactive varicosities that apposed on the membrane of a NRM neuron in slices from morphine-treated rats (Fig. 5). The number of neurons apposed by δ-opioid receptor-immunoreactive varicosities was also significantly increased. This increase was observed in a comparable total number of cells in each treatment group (Fig. 5C).

We have shown previously that a primary action of μ-opioid agonists producing behavioral analgesia in the NRM is inhibition of GABA synaptic transmission through presynaptic μ-opioid receptors (Pan et al., 1997). Then, the emergence of δ-opioid receptor-mediated inhibition of GABA IPSCs should lead to δ-opioid receptor-mediated analgesia in morphine-treated rats in vivo. In our next behavioral experiments, a single microinjection of deltorphin (1 μg) into the NRM did not significantly alter the baseline pain threshold measured by the tail-flick test on a freely moving rat in the placebo-treated group ($n = 4$ rats). However, in rats undergoing long-term morphine treatment ($n = 5$), the same dose and same NRM microinjection of deltorphin produced a significant antinociceptive effect that lasted approximately an hour (Fig. 6A). NRM comicroinjection of deltorphin with the δ-opioid receptor antagonist naltriben (20 ng) largely blocked this deltorphin effect ($n = 6$ rats), indicating a selective δ-opioid receptor-mediated effect. Further verifying this effect of δ-opioid receptors, NRM comicroinjection of the μ-opioid receptor antagonist CTAP (200 ng) abolished the antinociceptive effect induced by the μ-opioid receptor agonist DAMGO (1 μg, $n = 3$ rats in each group), but it did not significantly alter the deltorphin effect ($n = 3$, Fig. 6B). NRM microinjection of a higher dose of deltorphin (3 μg) in morphine-tolerant rats produced stronger analgesia, but it was only partially blocked by naltriben (data not shown).

Fig. 4. Long-term morphine treatment increases the total number of δ-opioid receptor-immunoreactive varicosities and colocalization of δ-opioid receptors and GAD in the NRM. A–C, confocal microscopic images of labeling for δ-opioid receptors (red), GAD (green), and colocalization of δ-opioid receptors and GAD (yellow, circled) in the NRM from a placebo-treated rat (A) and from a morphine-tolerant rat (B and C). Scale bar in A is 50 μm and applies to both A and B. Scale bar in C is 5 μm. D, summarized data of total δ-opioid receptors and GAD from the two groups of rats. ∗∗, $p < 0.01$.

Finally, we examined the deltorphin effect on analgesic tolerance induced by long-term treatment with morphine. Concerning the small residual effect of 1 μg of deltorphin that was resistant to δ-opioid receptor antagonist naltriben at a dose of 20 ng (Fig. 6A), we used a smaller dose of deltorphin (0.5 μg) to make sure that only the δ-opioid receptor was activated by deltorphin in examining its effect on morphine tolerance. In the groups of placebo-treated rats and morphine-treated rats with a single microinjection of saline into the NRM before morphine analgesia tests, the morphine dose-response curve in the morphine-treated rats was significantly shifted to the right by >8-fold compared with that in the placebo-treated rats, as measured by their estimated EC_{50} values (placebo-treated, 1.34 ± 0.15 mg/kg, $n = 6$; morphine-treated, 10.90 ± 1.25 mg/kg, $n = 6$; $p < 0.01$). This shift represents strong analgesic tolerance with much higher morphine concentrations required to produce comparable analgesic effects in morphine-treated rats (Fig. 6C). NRM microinjection of deltorphin (0.5 μg) had no apparent effect in the placebo-treated rats but significantly shifted the morphine dose-response curve to the left in the morphine-treated rats (placebo-treated, $EC_{50} = 1.19 \pm 0.28$ mg/kg, $n = 4$;

morphine-treated, $EC_{50} = 6.42 \pm 1.00$ mg/kg, $n = 4$), indicating a 41% reduction in the tolerance induced by long-term morphine treatment, as measured by change in the EC_{50} values (morphine-treated plus saline, 10.90 ± 1.25 mg/kg; morphine-treated plus deltorphin, 6.42 ± 1.00 mg/kg; $p < 0.01$, Fig. 6C). Although NRM microinjection of δ-opioid receptor antagonist naltriben (20 ng) did not significantly change the morphine dose-response curve in the placebo-treated rats ($EC_{50} = 1.43 \pm 0.21$ mg/kg, $n = 3$), it completely reversed the deltorphin effect when coinjected with deltorphin in the morphine-treated rats ($EC_{50} = 15.76 \pm 4.97$ mg/kg, $n = 5$, $p < 0.05$ compared with 6.42 ± 1.00 mg/kg for the group of NRM deltorphin alone), indicating a specific effect mediated by δ-opioid receptors (Fig. 6D).

Discussion

We have demonstrated that functional δ-opioid receptors, absent in morphine-naive rats, appear on GABAergic terminals to inhibit presynaptic GABA release in NRM neurons from morphine-tolerant rats. This emergence of δ-opioid receptor function is probably mediated by translocation of δ-opioid receptors to the surface membrane on GABA terminals. This notion is supported by the appearance of δ-opioid receptors in NRM preparations of membrane proteins, by an increased colocalization of δ-opioid receptors and GAD, and by the significant increase in the number of δ-opioid receptor-immunoreactive profiles that appose NRM neurons. The function of the emerged δ-opioid receptors is further supported by behavioral observations that activation of δ-opioid receptors becomes analgesic and relieves analgesic tolerance in morphine-tolerant rats.

Previous anatomical studies at light and electron microscopy levels have shown abundant immunoreactivity of δ-opioid receptors in brain areas involved in pain modulation, including several brainstem nuclei such as the periaqueductal gray, the NRM, and other raphe nuclei (Arvidsson et al., 1995; Cheng et al., 1995; Commons et al., 2001). The δ-opioid receptor in all these areas is predominantly present in presynaptic axon terminals, associated with large dense-core vesicles in the intracellular compartments but not on plasma membrane of synaptic boutons (Commons et al., 2001). Despite the presence of the δ-opioid receptor illustrated by immunocytochemistry in these areas, no δ-opioid receptor-mediated cellular action has been reported in those brainstem areas in normal conditions (Chieng and Christie, 1994; Fields, 2004). This indicates that these intracellularly localized δ-opioid receptors are not functional in normal conditions. Whereas a large proportion of immunoreactive δ-opioid receptors colocalize with enkephalin immunoreactivity in the brainstem (Arvidsson et al., 1995; Cheng et al., 1995), no colocalization of δ-opioid receptors and GABA immunoreactivity was observed in the periaqueductal gray under normal conditions (Commons et al., 2001). We also found no colocalization of δ-opioid receptors and GAD in the NRM from morphine-naive rats, consistent with our electrophysiological observation of a lack of δ-opioid receptor-mediated effect on presynaptic GABA release.

In the spinal cord, including the dorsal horn, immunoreactivity of δ-opioid receptors also has been shown predominantly in axon terminals, with some labeling for δ-opioid receptors on cell bodies (Arvidsson et al., 1995; Cheng et al.,


Fig. 5. Long-term morphine treatment increases the number of δ-opioid receptor-immunoreactive varicosities apposing NRM neurons. A, a representative confocal microscopic image showing δ-opioid receptor-immunoreactive varicosities (red, arrowheads) that do not appose to an Fluoro Nissl Green-labeled (green) NRM neuron from a placebo-treated rat. B, a confocal image showing δ-opioid receptor-immunoreactive varicosities that appose to a NRM neuron from a morphine-tolerant rat. Scale bar is 10 μm and applies to both A and B. C, summarized data of cell apposition of δ-opioid receptor-immunoreactive varicosities from the two groups of rats. **, $p < 0.01$.

1995). In contrast to the lack of δ-opioid receptor-mediated cellular effect in the brainstem, activation of spinal δ-opioid receptors inhibits glutamate synaptic current, with no effect on GABA synaptic transmission (Glaum et al., 1994; Kohno et al., 1999). From a behavioral standpoint, activation of spinal δ-opioid receptors produces significant analgesia under normal conditions (Standifer et al., 1994; Cahill et al., 2001).

It is increasingly recognized that opioid receptors, like other G protein-coupled receptors, undergo rapid and dynamic regulation by the mechanisms of receptor trafficking (Tan et al., 2004). As an initial step of receptor trafficking, receptor internalization has been extensively studied, and a mechanism involving G protein-coupled receptor kinase and β-arrestin has been demonstrated (Krupnick and Benovic, 1998). Several recent studies have reported the trafficking of opioid receptors stimulated by various conditions. In the spinal cord, density of postsynaptic δ-opioid receptors on cell bodies and δ-opioid receptor-mediated analgesic action are increased by 48-h morphine exposure (Cahill et al., 2001). Stress and inflammation increase the expression of δ-opioid receptors and the analgesic action of δ-opioid receptor agonists (Hurley and Hammond, 2000; Commons, 2003). As for the mechanisms for δ-opioid receptor insertion into surface membrane, recent studies have demonstrated in dorsal root ganglion neurons that interaction of the third luminal domain of δ-opioid receptors with the substance P domain of protachykinin sorts the δ-opioid receptor into large dense-core vesicles, leading to Ca^{2+}-dependent δ-opioid receptor insertion into surface membrane upon activation of vanilloid and $P2Y_1$ receptors (Bao et al., 2003; Guan et al., 2005). In addition, withdrawal from morphine induces δ-opioid receptor-mediated inhibition of GABA synaptic current in neurons of the periaqueductal gray (Hack et al., 2005). cAMP analogs induce β-arrestin-dependent inhibition of GABA IPSCs by μ-opioid receptors in the dorsal motor nucleus of the vagus

neurons (Browning et al., 2004). The current study further demonstrates with anatomical, molecular, cellular, and behavioral evidence that in an opioid-tolerant state, functional δ-opioid receptors appear on surface membrane of cell-apposing GABAergic terminals, inhibit GABA release, produce analgesia, and relieve morphine tolerance. The mechanism underlying δ-opioid receptor trafficking induced by long-term morphine treatment is currently unknown.

The evidence from the current study supports the increase in membrane δ-opioid receptors on presynaptic GABAergic terminals as the primary mechanism for the emerged cellular and behavioral actions of δ-opioid receptors. This does not exclude a possible mechanism of increased mRNA expression and protein synthesis for δ-opioid receptors, as our real-time RT-PCR experiment detected a moderate, although not statistically significant, increase (74%) in δ-opioid receptor mRNA levels after morphine treatment. The failure of the Western blotting experiment to detect any change in total proteins of δ-opioid receptors in the NRM may reflect the fact that the change was too small to be detected by the technique in our experimental conditions. Consistent with the PCR experiment for δ-opioid receptor mRNA, immunocytochemical analysis showed a significant and comparable increase (73.4%) in total immunoreactivity of δ-opioid receptors in the NRM of morphine-tolerant rats. The source of the translocated δ-opioid receptors on terminal membrane is currently unclear. They may come primarily from the intracellular pool of δ-opioid receptors. As discussed above, newly synthesized δ-opioid receptors may also contribute. Another possibility is that they are transported externally from the periaqueductal gray, because 50% of neurons in the periaqueductal gray projecting directly to the NRM express δ-opioid receptor mRNA (Wang and Wessendorf, 2002). It is noteworthy that the cellular action of δ-opioid receptors induced by long-term morphine treatment was observed in only approximately 45% of NRM neurons. The reason for this partial surface

Fig. 6. Long-term morphine treatment induces δ-opioid receptor-mediated analgesia and reduction of morphine tolerance in rats in vivo. A, effects of deltorphin microinjected into the NRM (arrow) on pain thresholds in placebo-treated rats (○) and in rats undergoing long-term treatment with morphine without (●) or with (■) NRM comicroinjection of naltriben. B, effects of NRM microinjection (arrow) with DAMGO (○), CTAP plus DAMGO (●), and CTAP plus deltorphin (■) on pain thresholds in morphine-tolerant rats. A statistical comparison was made between groups of CTAP plus DAMGO and CTAP plus deltorphin. C and D, morphine dose-response curves in placebo-treated rats (open symbols) and rats undergoing long-term treatment with morphine (filled symbols) with NRM microinjection of saline (circles, same data in C and D). Deltorphin was microinjected into the NRM in placebo-treated rats (C, □) and in morphine-treated rats (C, ■). Naltriben was microinjected into the NRM in placebo-treated rats (D, □), and naltriben plus deltorphin was microinjected into the NRM in morphine-treated rats (D, ■). MPE, maximum possible effect (see *Materials and Methods*). ∗, $p < 0.05$; ∗∗, $p < 0.01$.

expression of δ-opioid receptors among NRM cells is unclear at present. However, it is interesting to note that under opioid withdrawal conditions, the distribution of this functional δ-opioid receptors is increased to >90% of NRM cells (J. Ma and Z. Z. Pan, unpublished observations). This indicates that all these GABAergic terminals are capable of expressing the functional δ-opioid receptors, and the regulating mechanism is related to the magnitude of adaptations induced by long-term morphine treatment that are further augmented during opioid withdrawal.

The function of δ-opioid receptors in pain modulation has been particularly perplexing; agonists of δ-opioid receptors generally produce little to weak analgesic effect under normal conditions in both animal studies and clinical applications (Kovelowski et al., 1999; Inturrisi, 2002; Hurley et al., 2003; Fields, 2004; Scherrer et al., 2004). This can be largely attributed to the lack of functional δ-opioid receptors in the brain with the analgesia mediated only by spiral δ-opioid receptors. Synergism of δ-opioid receptors and μ-opioid receptors in producing analgesia has been reported (Kovelowski et al., 1999; Schmidt et al., 2002; Gomes et al., 2004). In δ-opioid receptor knockout mice, spinal δ-opioid receptor-mediated analgesia is nearly abolished, but agonists of δ-opioid receptors retain their supraspinal analgesic potency, which is insensitive to antagonists of δ-opioid receptors (Zhu et al., 1999). This retained analgesia mediated by agonists of δ-opioid receptors in δ-opioid receptor knockout mice has been found later to be abolished by antagonists of μ-opioid receptors (Kieffer, 2000; Scherrer et al., 2004). In δ-opioid receptor-deficient mice, δ-opioid receptor agonist-mediated analgesia is attenuated (Matthes et al., 1998). These findings question the receptor selectivity of δ-opioid receptor agonists applied systemically in vivo without confirmation by δ-opioid receptor antagonists and argue that some of the analgesia induced by agonists of δ-opioid receptors is actually mediated by μ-opioid receptors. The current study shows that long-term morphine treatment induces δ-opioid receptor-mediated analgesia probably through inhibition of GABA synaptic transmission via emerged δ-opioid receptors on GABAergic terminals in the NRM neurons. This disinhibition mechanism for analgesia by μ-opioid receptor agonists in the NRM has been demonstrated in our previous studies (Pan et al., 1990, 1997). As expected, the emerged analgesia mediated by δ-opioid receptors adds to the analgesic effect of morphine and relieves morphine tolerance. The findings of this study reveal a compensatory analgesic function of δ-opioid receptors and its functional interaction with μ-opioid receptors in a condition of chronically stimulated μ-opioid receptors. With enhanced analgesia and reduced tolerance in an opioid-tolerant state, agonists of δ-opioid receptors may hold great promise as better analgesics or adjuvant analgesics to improve current opioid therapies based on agonists of μ-opioid receptors for the treatment of chronic pain.

References

Arvidsson U, Dado RJ, Riedl M, Lee JH, Law PY, Loh HH, Elde R, and Wessendorf MW (1995) delta-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. *J Neurosci* **15:**1215–1235.

Bao L, Jin SX, Zhang C, Wang LH, Xu ZZ, Zhang FX, Wang LC, Ning FS, Cai HJ, Guan JS, et al. (2003) Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. *Neuron* **37:**121–133.

Bie B, Peng Y, Zhang Y, and Pan ZZ (2005) cAMP-mediated mechanisms for pain sensitization during opioid withdrawal. *J Neurosci* **25:**3824–3832.

Browning KN, Kalyuzhny AE, and Travagli RA (2004) Mu-opioid receptor trafficking on inhibitory synapses in the rat brainstem. *J Neurosci* **24:**7344–7352.

Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, and Beaudet A (2001) Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. *J Neurosci* **21:**7598–7607.

Cheng PY, Svingos AL, Wang H, Clarke CL, Jenab S, Beczkowska IW, Inturrisi CE, and Pickel VM (1995) Ultrastructural immunolabeling shows prominent presynaptic vesicular localization of delta-opioid receptor within both enkephalin- and nonenkephalin-containing axon terminals in the superficial layers of the rat cervical spinal cord. *J Neurosci* **15:**5976–5988.

Chieng B and Christie MJ (1994) Inhibition by opioids acting on mu-receptors of GABAergic and glutamatergic postsynaptic potentials in single rat periaqueductal gray neurones in vitro. *Br J Pharmacol* **113:**303–309.

Commons KG (2003) Translocation of presynaptic delta opioid receptors in the ventrolateral periaqueductal gray after swim stress. *J Comp Neurol* **464:**197–207.

Commons KG, Beck SG, Rudoy C, and Van Bockstaele EJ (2001) Anatomical evidence for presynaptic modulation by the delta opioid receptor in the ventrolateral periaqueductal gray of the rat. *J Comp Neurol* **430:**200–208.

Fields HL (2004) State-dependent opioid control of pain. *Nat Rev Neurosci* **5:**565–575.

Glaum SR, Miller RJ, and Hammond DL (1994) Inhibitory actions of delta 1-, delta 2- and mu-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord. *J Neurosci* **14:**4965–4971.

Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, and Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. *Proc Natl Acad Sci USA* **101:**5135–5139.

Guan J-S, Xu ZZ, Gao H, He SQ, Ma GQ, Sun T, Wang LH, Zhang ZN, Lena I, Kitchen I, et al. (2005) Interaction with vesicle luminal protachykinin regulates surface expression of delta opioid receptors and opioid analgesia. *Cell* **122:**619–631.

Hack SP, Bagley EE, Chieng BC, and Christie MJ (2005) Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. *J Neurosci* **25:**3192–3198.

Hurley RW, Banfor P, and Hammond DL (2003) Spinal pharmacology of antinociception produced by microinjection of mu or delta opioid receptor agonists in the ventromedial medulla of the rat. *Neuroscience* **118:**789–796.

Hurley RW and Hammond DL (2000) The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. *J Neurosci* **20:**1249–1259.

Ingram SL, Vaughan CW, Bagley EE, Connor M, and Christie MJ (1998) Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. *J Neurosci* **18:**10269–10276.

Inturrisi CE (2002) Clinical pharmacology of opioids for pain. *Clin J Pain* **18:**S3–S13.

Kalyuzhny AE, Arvidsson U, Wu W, and Wessendorf MW (1996) mu-Opioid and delta-opioid receptors are expressed in brainstem antinociceptive circuits: studies using immunocytochemistry and retrograde tract-tracing. *J Neurosci* **16:**6490–6503.

Kalyuzhny AE and Wessendorf MW (1998) Relationship of mu- and delta-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits. *J Comp Neurol* **392:**528–547.

Kieffer BL (2000) Opioid receptors: from genes to mice. *J Pain* **1:**45–50.

Kohno T, Kumamoto E, Higashi H, Shimoji K, and Yoshimura M (1999) Actions of opioids on excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord. *J Physiol* **518 (Pt 3):**803–813.

Kovelowski CJ, Bian D, Hruby VJ, Lai J, Ossipov MH, and Porreca F (1999) Selective opioid delta agonists elicit antinociceptive supraspinal/spinal synergy in the rat. *Brain Res* **843:**12–17.

Krupnick JG and Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* **38:**289–319.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ method. *Methods* **25:**402–408.

Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature (Lond)* **383:**819–823.

Matthes HW, Smadja C, Valverde O, Vonesch JL, Foutz AS, Boudinot E, Denavit-Saubie M, Severini C, Negri L, Roques BP, et al. (1998) Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. *J Neurosci* **18:**7285–7295.

Pan ZZ (2003) Opioid tolerance in adult and neonatal rats, in *Opioid Research: Methods and Protocols* (Pan ZZ ed), pp 223–232, Humana Press, Totowa, NJ.

Pan ZZ, Tershner SA, and Fields HL (1997) Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor. *Nature (Lond)* **389:**382–385.

Pan ZZ, Williams JT, and Osborne PB (1990) Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro. *J Physiol* **427:**519–532.

Paxinos G and Watson C (1986) *The Rat Brain in Stereotaxic Coordinates*, 2nd ed, Academic Press, Sydney.

Quinn B, Toga AW, Motamed S, and Merlic CA (1995) Fluoro nissl green: a novel fluorescent counterstain for neuroanatomy. *Neurosci Lett* **184:**169–172.

Scherrer G, Befort K, Contet C, Becker J, Matifas A, and Kieffer BL (2004) The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. *Eur J Neurosci* **19:**2239–2248.

Schmidt BL, Tambeli CH, Levine JD, and Gear RW (2002) mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat. *Eur J Neurosci* **15:**861–868.

Scholz J and Woolf CJ (2002) Can we conquer pain? *Nat Neurosci* **5 (Suppl):**1062–1067.

Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, and Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. *Proc Natl Acad Sci USA* **94:**1544–1549.

Standifer KM, Chien CC, Wahlestedt C, Brown GP, and Pasternak GW (1994) Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. *Neuron* **12:**805–810.

Tan CM, Brady AE, Nickols HH, Wang Q, and Limbird LE (2004) Membrane trafficking of G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* **44:**559–609.

Wang H and Wessendorf MW (2002) Mu- and delta-opioid receptor mRNAs are expressed in periaqueductal gray neurons projecting to the rostral ventromedial medulla. *Neuroscience* **109:**619–634.

Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, and Pintar JE (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. *Neuron* **24:**243–252.

Address correspondence to: Dr. Zhizhong Z. Pan, Department of Anesthesiology and Pain Medicine, Unit 110, University of Texas-MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: zzpan@mdanderson.org